Charles Olson, MD
Interventional Cardiology · Omaha, NENPI 1699736553
Payments from drug & device makers
Across 441 payments — averaging $262.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$78K
- Bayer$13K
- Janssen Research & Development, LLC$10K
- Edwards Lifesciences$4K
- Amgen$3K
- Medtronic$2K
- plus $6K from 33 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $78,141 |
| Bayer | 7 | $12,822 |
| Janssen Research & Development, LLC | 2 | $9,500 |
| Edwards Lifesciences | 120 | $3,896 |
| Amgen | 12 | $3,059 |
| Medtronic(2 entities) | 79 | $2,256 |
| Abbott | 38 | $2,224 |
| Novo Nordisk AS | 50 | $1,423 |
| Boston Scientific | 27 | $820 |
| Abiomed | 6 | $458 |
| Sanofi-aventis U.S. LLC | 11 | $167 |
| Philips North America LLC | 3 | $159 |
| AstraZeneca | 3 | $111 |
| Amarin Pharma, Inc. | 7 | $108 |
| Boehringer Ingelheim | 6 | $91 |
| Bridgebio Pharma, Inc. | 2 | $66 |
| Cardiva Medical, Inc. | 2 | $59 |
| Scpharmaceuticals Inc. | 3 | $57 |
| Gilead | 4 | $52 |
| Shockwave Medical, Inc | 1 | $44 |
| Merck | 3 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Johnson & Johnson | 3 | $38 |
| Terumo Medical Corporation | 2 | $27 |
| Sanofi | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Pfizer | 2 | $24 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Zimmer Biomet | 1 | $20 |
| Atricure, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Opsens Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $13 |
| Penumbra, Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $11 |
How this compares
$115,964 in reported general payments places this provider in the 80th percentile of 50 interventional cardiology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other interventional cardiology in Omaha
- Himanshu AgarwalOmaha$5.6M
- Andrew GoldsweigOmaha$711K
- Poonam VelagapudiOmaha$142K
- Haysam AkkadOmaha$63K
- Jai ParekhOmaha$44K
- Edmund FiksinskiOmaha$23K
- Scott CarolloOmaha$19K
- Shahbaz MalikOmaha$17K
- Toufik HaddadOmaha$14K
- Ajaypaul SukhiOmaha$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.